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Abstract: Background: Currently, proposed nomograms are mainly based on post-operative
histopathology. The purpose of this study was to identify preoperative computed tomography
(CT) and clinical information that allow prediction of disease-free (DFS) and overall survival (OS)
of patients surgically treated for pancreatic head cancer. Methods: A total of 136 patients who
underwent curative-intent surgery were retrospectively reviewed. Based on results from multivariate
Cox regression analysis, a prediction model was constructed with preoperative CT features and
clinical information. Overall performance of the nomogram was calculated by Harrell’s C-index.
Results: Symptoms at diagnosis, preoperative serum CA 19-9 ≥ 34 U/mL, and four imaging features
(necrosis (DFS, P = 0.066; OS, P = 0.002), possible venous invasion (DFS, P = 0.150, OS, P = 0.055),
suspected metastatic regional lymph node (DFS, P = 0.001; OS, P = 0.099), and associated pancreatitis
or pseudocyst (DFS, P = 0.013; OS, P = 0.041)) were included to build the nomogram. The c-statistics
for the discrimination power of the proposed nomogram was 0.6496 for DFS and 0.6746 for OS.
Conclusion: A nomogram derived from preoperative CT and clinical information could estimate
the risk of recurrence and all-cause death after curative-intent surgery for radiologically resectable
pancreatic head cancer.
Keywords: pancreatic cancer; pancreatic head cancer; nomogram; computed tomography
(CT); prognosis
1. Introduction
Pancreatic cancer is the fourth leading cause of cancer-related mortality [1]. Because it tends
to be detected in advanced stages, only 20% of newly diagnosed patients are thought to be surgical
candidates [2]. The suspected invasion of major vessels around the pancreas, evaluated on computed
tomography (CT) or magnetic resonance imaging (MRI), is the key feature to deciding resectability [3,4].
Recently, the possibility of surgical resectability has expanded, with advances in imaging and surgical
techniques [5]. However, the oncologic outcomes of resected pancreatic cancer are still disappointing.
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The one- and five-year survival rate is approximately 60–77.8% and 20–31.3%, respectively [6–8],
and reported median overall survival is 17–22.8 months after macroscopically complete removal of
cancer. Approximately half of patients who undergo curative-intent surgery for pancreatic cancer
experience recurrence within a year [8,9]. Moreover, pancreatectomy is a high-risk procedure.
Perioperative mortality has declined to less than 3–4% over the past decade, owing to the increased
experience of dedicated pancreatic surgeons who mostly work at specialized centers [10]. However,
perioperative morbidity still remains high.
Considering the perioperative morbidity and early recurrence after standard surgical treatment
and improved results of neoadjuvant therapy with the introduction of new chemotherapeutic agents
such as NAB-paclitaxel (Abraxane®; Abraxis BioScience LLC, Summit, NJ, USA) in addition to the
FOLFIRINOX (combination of folinic acid, fluorouracil, irinotecan, and oxaliplatin) regimen [11,12],
appropriate patient selection is crucial to achieve the best surgical and oncologic outcomes. With the
exception of several clinical factors reported to be related with the survival of pancreatic cancer
patients such as age [13], gender [13], performance status [14], or serum CA 19-9 [15], generally
accepted prognostic factors are mainly related to postoperative histopathologic examinations [16,17].
A prognostic nomogram, previously developed with data from a large population and externally
validated, was also based on postoperative histopathology [18]. If we can predict the clinical course
of a patient after curative-intent surgery based on preoperatively identified information, it can help
surgeons select optimal surgical candidates and choose management approaches reflecting individual
patient preference and expected quality of life.
Hence, the purpose of this study was to identify preoperative clinical and radiologic parameters
to predict one- and five-year disease-free survival (DFS) and overall survival (OS) in patients who
underwent curative-intent pancreatectomy for pancreatic cancer without neoadjuvant therapy.
2. Materials and Methods
2.1. Study Population and Clinical Information
The institutional review board of our institution approved this retrospective study and waived
the requirement for informed consent. One hundred and fifty-five patients who underwent surgical
treatment aiming to cure pancreatic head or neck adenocarcinoma without neoadjuvant therapy were
registered in the surgical database of our institution from February 2005 to December 2016. Seventeen
patients were excluded from analysis because the quality of their preoperative CT images was not
enough for evaluation. Two patients, who expired within 30 days after surgery, were excluded to
remove cases of perioperative mortality. Therefore, the final study population included 136 patients.
The following clinical information, laboratory data, and pathology reports were collected prospectively
as part of routine practice by a clinical research nurse: Gender, age, body mass index (BMI), presence
of symptoms at diagnosis, serum CA 19-9, serum total bilirubin, serum albumin, prognostic nutritional
index (10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm3)) [19], type of surgery,
surgical resection of major vessels or adjacent organs, adjuvant chemotherapy, pathologic tumor size,
histologic differentiation, pathologic T stage, presence of lymph node (LN) metastasis, LN ratio (total
number of metastatic LNs divided by total number of retrieved LNs), microscopic perineural invasion,
lymphovascular invasion, involvement of resection margins, presence of event (recurrence or death),
and time to event.
2.2. CT Imaging
Preoperative CT was performed using various machines and protocols with intravenous contrast
agents. If there was at least one portal venous phase (PVP) CT of acceptable quality, it was used for
analysis. If multiple phases of acceptable quality were available, all CT images were reviewed in the
order of PVP, pre-contrast, and arterial phase (AP).
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2.3. Image Analysis
All CT images were retrospectively reviewed using a Picture Archiving and Communication
System (Centricity, Version 4.0, GE Healthcare, Barrington, IL, USA). Two board-certified abdominal
radiologists (S.H.H. and Y.E.C., with 2 and 11 years of experience dedicated to abdominal radiology,
respectively) independently reviewed images for qualitative analysis. Both were blinded to each
patient’s clinical data. For every patient, each investigator determined suspicion for malignancy,
invasion of common bile duct (CBD) or duodenum, involvement of uncinate process or neck, presence
of peripancreatic fat invasion, retroperitoneal margin status, presence of necrosis (centrally located
cystic change of the tumor with irregular internal margin), hyperenhancement of tumor (equal or
brighter than pancreatic parenchyma in the hepatic venous phase (HVP)), worrisome finding for
invasion of major vessels (celiac artery, superior mesenteric artery (SMA), gastroduodenal artery (GDA),
portal vein (PV), and superior mesenteric vein (SMV)) according to the National Comprehensive
Cancer Network (NCCN) criteria [20], presence of LN suspicious for metastasis in regional and
retroperitoneal space (short diameter > 8 mm for regional and > 10 mm for retroperitoneal station,
round, irregular or necrotic change), degree of remnant pancreatic parenchymal atrophy (none to
mild versus moderate to severe), presence of underlying chronic pancreatitis suspected on CT (at least
two of the following features; pancreatic parenchymal calcification, pancreatolith, irregular dilatation
of main pancreatic duct (MPD), and diffuse pancreatic atrophy), presence of acute pancreatitis or
pseudocyst, and overall radiologists’ conclusion for resectability (resectable or borderline resectable).
A pseudocyst was considered over a retention cyst when there was inflammatory change around
the lesion or lesional wall thickening [21]. After individual review, the two reviewers met to reach a
consensus on discordant results.
Quantitative analysis was performed by one radiologist (S.H.H.). The longest diameter of the
tumor and the MPD were measured. The size of the tumor was measured at either AP or PVP, at
whichever the tumor was most clearly demarcated. Finally, the TNM stage was calculated automatically
according to the seventh and eighth editions of the American Joint Committee on Cancer (AJCC).
Based on prospective records of clinical recurrence, one radiologist (S.H.H.) retrospectively
reviewed each patient’s CTs and determined the actual time of tumor recurrence.
2.4. Statistical Analysis
Univariate and multivariate Cox regression analyses were performed to identify preoperative
clinical information and CT findings associated with tumor recurrence and OS. Factors which achieved
statistical significance in the univariate Cox model or were considered as important for oncologic
outcome by investigators were included in the multivariate Cox analysis. A prediction model was
derived from the multivariate Cox analysis, and a nomogram was constructed using the package
survival and rms of R version 3.1.3 (http://www.r-project.org). The serum CA19-9 was dichotomized
at 34 U/mL, which was chosen by the log-rank test using the Contal and O’Quigley method [22].
Harrell’s C-index was measured to evaluate the discriminative ability of the final model. Calibration
performance was evaluated by calibration plots.
Internal validation was performed by measuring Harrell’s C-index and incremental area under
curve (iAUC) using 200 bootstrapped resamples. Kaplan-Meier curves of the two risk groups based
on the predicted probability of event according to the proposed nomogram were compared using
the log-rank test. A subgroup analysis was performed on the 82 patients with resectable pancreatic
cancer. To identify clinical and pathologic characteristics according to risk, the Mann-Whitney U test
and Chi-square test were performed. Continuous variables were described as medians ± standard
deviations, and categorical variables were described as frequencies (%). Two-sided P values < 0.05
were considered statistically significant. All statistical analyses were performed using SAS version 9.4
(SAS Institute, Cary, NC, USA).
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3. Results
3.1. Patient Demographics
Of 136 included patients, 77 (56.6%) were male and 59 (43.4%) were female. The median age was
66 (range: 41–81) years and median BMI was 22.7 (range: 15.9–32.3). Of all patients, 77.9% (106 of
136) were symptomatic. Median preoperative serum CA 19-9 was 119.7 U/mL (range: 0.1–13,800.0)
and median serum total bilirubin was 2.3 mg/dL (range: 0.1–38.3). In 74.3% (101 of 136) of patients,
serum CA 19-9 was above 34 U/mL. In preoperative CT, the median maximal diameter of the tumor
was 23.6 mm (range: 11.8–50.2). Eighty-two (60.3%) patients had resectable tumors and 54 (39.7%)
had borderline resectable tumors. Most patients (92.6%, 126 of 136) underwent pylorus-preserving
pancreaticoduodenectomy and the remaining 10 patients underwent Whipple’s operation. Combined
vascular resection was performed in 36 (26.5%) patients. In postoperative pathologic examination, the
median maximum diameter of the cancer was 25.0 mm (range: 12–70). One hundred and nine patients
(80.1%) were moderately differentiated. Lymphovascular and perineural invasion were observed in
65 (47.8 %) and 113 (83.1%) patients, respectively. Lymph node metastasis was found in 87 (64.0%)
patients. Resection margin was involved in 23 (16.9%). Most patients (80.1%, 109 of 136) received
postoperative adjuvant chemotherapy. The median duration of follow-up was 527.5 days (range:
106–2710) after surgery. During follow-up, 95 (69.9%) patients developed tumor recurrence and 73
(53.7%) died (Table 1).
Table 1. Baseline characteristics of the 136 included patients.
Characteristics Total
Clinical information
Age (years) 66 (41–81)
Gender
Male 77 (56.6%)
Female 59 (43.4%)
BMI (kg/m2) 22.7 (15.9–32.3)
PNI 48.2 (30.4–60.1)
Symptoms at diagnosis † 106 (77.9%)
Preoperative serum CA19-9 (continuous) (U/mL) 119.7 (0.1–13,800.0)
Serum total bilirubin at diagnosis (mg/dL) 2.3 (0.1–38.3)
Serum albumin at diagnosis (mg/dL) 4.0 (2.7–5.0)
Type of surgery
Whipple’s operation 10 (7.4 %)
PPPD 126 (92.6%)
Combined vascular resection 36 (26.5%)
Adjuvant chemotherapy 109 (80.1%)
CT findings
Size (mm) 23.6 (11.8–50.2)
Radiologists’ conclusion for resectability
Resectable 82 (60.3%)
Borderline resectable 54 (39.7%)
Pathologic findings
Size (mm) 25.0 (12–70)
Differentiation
Well 15 (11.0%)
Moderate 109 (80.1%)
Poorly 12 (8.8%)
Lymphovascular invasion 65 (47.8%)
Perineural invasion 113 (83.1%)
Lymph node metastasis 87 (64.0%)
Resection margin
Negative 113 (83.1%)
Positive 23 (16.9%)
† Jaundice (n = 65), abdominal pain (n = 48), weight loss/anorexia (n = 22), nausea and/or vomiting (n = 4); one patient
reported multiple symptoms. Continuous variables are displayed as medians, with ranges in parentheses; BMI,
body mass index; CA 19-9, carbohydrate antigen 19-9; PPPD, pylorus-preserving pancreaticoduodenectomy; CT,
computed tomography.
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3.2. Correlation between Preoperative Clinically Detectable Parameters and Long-Term Oncologic Outcomes
Following Pancreatectomy
In the univariate Cox regression for DFS, symptoms at diagnosis (P = 0.006), preoperative serum
CA19-9 (P = 0.053), serum total bilirubin (P = 0.001), tumor size on CT (P = 0.045), CBD invasion
on CT (P = 0.014), PV or SMV invasion on CT (P = 0.011), and borderline resectable tumors on CT
(P = 0.028) were statistically significant preoperative parameters. The preoperative CT findings of
uncinate process involvement (P = 0.066) and necrosis (P = 0.094) showed similar tendency without
statistical significance. Multivariate analysis identified symptoms at diagnosis (Hazard ratio (HR),
2.01; 95% CI, 1.12–3.62; P = 0.020), PV or SMV invasion on CT (HR, 2.07; 95% CI, 1.35–3.19; P = 0.001),
and associated pancreatitis or pseudocysts (HR, 0.51; 95% CI, 0.30–0.86; P = 0.013) as independent
prognostic factors for tumor recurrence. Preoperative serum CA19-9 (HR, 1.63; 95% CI, 0.97–2.72,
P = 0.065) and necrosis on CT (HR, 1.64; 95% CI, 0.97–2.79, P = 0.066) showed marginal significance
(Table S1).
In the univariate Cox regression for OS, symptoms at diagnosis (P = 0.037), preoperative serum
CA19-9 (P = 0.007), necrosis on CT (P = 0.001), and PV invasion on CT (P = 0.011) were statistically
significant preoperative parameters. Serum total bilirubin (P = 0.074), presence of suspected metastatic
retroperitoneal LN on CT (P = 0.081), and moderate to severe degree of pancreatic parenchymal
atrophy on CT (P = 0.093) showed marginal significance. Subsequent multivariate analyses identified
preoperative serum CA19-9 (HR, 2.29; 95% CI, 1.19–4.39, P = 0.013), necrosis on CT (HR, 2.42; 95% CI,
1.39–4.21, P = 0.002) and associated pancreatitis or pseudocysts (HR, 0.54; 95% CI, 0.30–0.98; P = 0.041)
as independent prognostic factors for overall survival. Symptoms at diagnosis (HR, 1.68; 95% CI,
0.88-3.22; P = 0.115), PV or SMV invasion on CT (HR, 1.53; 95% CI, 0.92–2.54; P = 0.099), and presence
of suspicious regional LN on CT (HR, 1.67; 95% CI, 0.99–2.81; P = 0.055) showed marginal significance
(Table S2).
3.3. Subgroup Analysis of the 82 Patients with Resectable Pancreatic Cancer
In the univariate Cox regression for DFS, symptoms at diagnosis (P = 0.013), preoperative serum
CA19-9 (P = 0.027), serum total bilirubin (P = 0.009), and tumor size on CT (P = 0.042) were statistically
significant preoperative parameters. The preoperative CT findings of CBD invasion on CT (P = 0.065),
duodenal invasion (P = 0.105), necrosis (P = 0.056), and associated pancreatitis or pseudocyst on CT
(P = 0.054) showed similar tendency without statistical significance (Table S3). In multivariate analysis,
symptoms at diagnosis (P = 0.027), preoperative serum CA 19-9 ≥ 34 U/mL (P = 0.043), and associated
pancreatitis or pseudocyst on CT (P = 0.018) were significant prognostic factors, whereas necrosis on
CT (P = 0.325), which was marginally significant in all cases, was not (Table S4).
In the univariate Cox regression for OS, symptoms at diagnosis (P = 0.027), preoperative serum
CA19-9 (P = 0.027), serum total bilirubin (P = 0.008), serum albumin (P = 0.017), and necrosis on CT
(P = 0.003) were statistically significant preoperative parameters. Presence of retroperitoneal LN on CT
(P = 0.071) showed marginal significance (Table S5). In univariate analysis, preoperative serum CA19-9
(P = 0.021) and necrosis on CT (P = 0.045) were significant prognostic factors, whereas associated
pancreatitis or pseudocyst on CT (P = 0.131), which was significant in all cases, was not (Table S4).
3.4. Developing a Preoperative Clinical and Imaging-Based Nomogram to Predict DFS and OS
Based on the results of multivariate analysis, a nomogram to predict one- and five- year DFS
and OS was derived (Figure 1). The nomogram included six preoperative parameters: Presence of
symptoms at diagnosis, preoperative serum CA 19-9 dichotomized at 34 U/mL, necrosis on CT, PV or
SMV invasion on CT, presence of suspected metastatic regional LN on CT, and associated pancreatitis
or pseudocyst on CT (Figure 2).
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pancreatic head cancer. The points of each predictor found on the uppermost point scale were added 
up and the total sum projected on the bottom point scale indicates the probability of (a) disease-free 
and (b) overall survival for each time point. The serum CA 19-9 was dichotomized at 34 U/mL by the 
log-rank test; CA 19-9, carbohydrate antigen 19-9; CT, computed tomography; 0, Negative; 1, Positive. 
Figure 1. Nomogram predicts probability of (a) disease-free survival and (b) overall survival one
year and five years after curative-intent surgery for radiologically resectable or borderline resectable
pancreatic head cancer. The points of each predictor found on the uppermost point scale were added
up and the total sum projected on the bottom point scale indicates the probability of (a) disease-free
and (b) overall survival for each time point. The serum CA 19-9 was dichotomized at 34 U/mL by the
log-rank test; CA 19-9, carbohydrate antigen 19-9; CT, computed tomography; 0, Negative; 1, Positive.
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it t e adjuvant therapy. Presence of (a) necrosis (centrally located cystic change of the tumor with
irregular internal margin), (b) worrisome finding for invasio of PV or SMV according to the NCCN
guidelines, (c) suspected metastatic regional lymph node (short diameter > 8 mm, round, irregular
or necrotic change), and (d) associated pancreatitis or pseudocyst on CT. DFS, disease-free survival;
OS, overall survival; PV, portal vein; SMV, superior mesenteric vein; NCCN, National Comprehensive
Cancer Network; CT, computed tomography.
3.5. Calibration and Internal Validation
The model performance, quantified by Harrell’s c-statistics, was 0.6496 (standard error (SE) =
0.0325) for DFS and 0.6746 (SE = 0.0384) for OS (Table 2). Calibration plots showed good agreement
between actual and predicted probability for both DFS and OS (Figure 3).
Table 2. Preoperative parameters to predict disease-free survival and overall survival of patients with
resectable pancreatic cancer.
Parameters
Disease-Free Survival Overall Survival
HR 95% CI P Value HR 95% CI P Value
Symptoms t diag osis 2.01 1.12–3.62 0.020 1.68 0.88–3.22 0.115
Preoperative serum CA 19-9 ≥ 34 U/mL 1.63 0.97–2.72 0.065 2.29 1.19–4.39 0.013
Necrosis on CT 1.64 0.97–2.79 0.066 2.42 1.39–4.21 0.002
PV or SMV invasion on CT 1.4 0.89–2.21 0.150 1.67 0.99–2.81 0.055
Regional LN suspicious for metastasis on CT 2.07 1.35–3.19 0.001 1.53 0.92–2.54 0.099
Associated pancreatitis or pseudocyst on CT 0.51 0.30–0.86 0.013 0.54 0.30–0.98 0.041
Harrell’s c-statistics 0.6496 (0.0325) 0.6746 (0.0384)
Numbers in parentheses are standard errors. HR, hazard ratio; CI, confidence interval; CA 19-9, carbohydrate
antigen 19-9; CT, computed tomography; PV, portal vein; SMV, superior mesenteric vein; LN, lymph node; AIC,
Akaike information criterion.
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Internal validation performed using 200 bootstrap resampling revealed that Harrell’s C-index and
iAUC of the suggested nomogram was 0.564 (95% CI, 0.527–0.608) and 0.556 (95% CI, 0.505–0.604) for
DFS, and 0.579 (95% CI, 0.525–0.633) and 0.579 (95% CI, 0.536–0.626) for OS, respectively.
The ‘apparent’ curve was calculated directly from the dataset. The ‘bias-corrected’ curve was
adjusted by bootstrap with 200 resamples.
3.6. Risk Stratification According to the Proposed Nomogram to Predict Oncologic Outcomes in Resected
Pancreatic Cancer Without Neoadjuvant Treatm nt
Based on the 50% probability of five-year survival calculated from the nomogram, patients were
divided into low- and high-risk groups. There were statistically significant differences between risk
groups regarding both DFS and OS (both P < 0.001; Figure 4). For predicting DFS, there were significant
differences in preoperative serum CA 19-9, tumor size, and presence of LN metastasis revealed in
postoperative histopathologic examinations between the two groups. Risk groups for predicting OS
also showed similar tendency, but only preoperative serum CA 19-9 reached statistical significance
(Table 3). There were no significant differences in the proportion of patients receiving adjuvant
chemotherapy (P = 0.465 for RFS, P = 0.156 for OS) or the type of chemotherapy regimen (P = 0.607 for
DFS, P = 0.882 for OS).
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 9 of 14 
 
 
(d) 
Figure 3. Calibration plots comparing predi ed and actual one- and five-year (a,b) disease-free 
survival and (c,d) overall surviv l. 
The ‘ pparent’ curve was calculated directly fro  the dataset. The ‘bias- orrected’ curve was 
adjusted y bootstrap with 200 resampl s. 
3.6 Risk Stratification According to the Proposed Nomogram to Predict Oncologic Outcomes in Resected 
Pancreatic Cancer Without Neoadjuvant Treatment 
Based on the 50% probability of five-year survival calculated from the nomogram, patients were 
divided into low- and high-risk groups. There were statistically significant differences between risk 
groups regarding both DFS and OS (both P < 0.001; Figure 4). For predicting DFS, there were 
significant differences in preoperative serum CA 19-9, tumor size, and presence of LN metastasis 
revealed in postoperative histopathologic examinations between the two s. Risk groups for 
predicting OS also showed similar tendency, but only p eoperative serum CA 19-9 rea hed statistical 
significance (Table 3). There were no significant differ nces in the proportio  of patients receiving 
adjuvant chemotherapy (P = 0.465 for RFS, P = 0.156 for OS) or the type of chemotherapy regimen (P 
= 0.607 for DFS, P = 0.882 for OS). 
 
Figure 4. Risk stratification according to the calculated probability of five-year (A) disease-free 
survival and (B) overall survival. 
Figure 4. Risk stratification according to the calculated probability of five-year (a) disease-free survival
and (b) overall survival.
J. Clin. Med. 2019, 8, 1749 10 of 14
High- and low- risk groups were dichotomized at 50% of the nomogram-based calculated
probability of recurrence.
Table 3. Clinical and pathologic characteristics of proposed nomogram-based risk groups. CA 19-9,
carbohydrate antigen 19-9; CT, computed tomography; AJCC, American Joint Committee on Cancer.
Chracteristics
Disease-Free Survival Overall Survival
Low-Risk
(n = 69)
High-Risk
(n = 67) P Value
Low-Risk
(n = 72)
High-Risk
(n = 64) P Value
Clinical information
Age, year (Q1–Q3) 66 (62–71) 64 (55–71) 0.237 66 (58.5–71) 65.5 (59–71) 0.843
Gender 0.712 0.791
Male 38 (55.1%) 39 (58.2%) 40 (55.6%) 37 (57.8%)
Female 31 (44.9%) 28 (41.8%) 32 (44.4%) 27 (42.2%)
Preoperative serum CA
19-9(continuous), U/mL (Q1–Q3)
56.0
(26.2–28.6)
203.9
(49.2–734.8) 0.003
54.0
(19.9–212.6)
295.0
(97.6–772.0) <0.001
Adjuvant chemotherapy 57(82.6%) 52(77.6%) 0.4652 61 (84.7%) 48 (75.0%) 0.156
Gemcitabine-based 42 (53.8%) 36 (46.2%)
0.607
44 (56.4%) 34 (46.6%)
0.882
Other 15 (48.4%) 16 (51.6%) 17 (54.8%) 14 (45.2%)
Pathologic findings
Size, mm (Q1–Q3) 23 (20–30) 26 (22–32) 0.019 23.5 (20–30) 25.5 (22–30) 0.057
Peripancreatic fat invasion 68 (98.6%) 67 (100.0 %) >0.999 71 (98.6%) 64 (100.0%) >0.999
Differentiation 0.741 0.844
Well 7 (10.1%) 8 (11.9%) 7 (9.7%) 8 (12.5%)
Moderate 57 (82.6%) 52 (77.6%) 59 (82.0%) 50 (78.1%)
Poorly 5 (7.2%) 7 (10.4%) 6 (8.3%) 6 (9.4%)
Lymphovascular invasion 31 (45.6%) 30 (44.8%) 0.925 34 (47.9%) 29 (45.3%) 0.765
Perineural invasion 56 (82.4%) 57(85.1%) 0.669 60 (84.5%) 53 (82.8%) 0.790
Lymph node metastasis 38 (55.1%) 49 (73.1%) 0.028 41 (56.9%) 46 (71.9%) 0.070
Lymph node ratio (Q1–Q3) 0.04 (0–0.15) 0.06 (0–0.18) 0.143 0.06 (0–0.15) 0.06 (0–0.18) 0.306
Resection margin positive 9 (13.0%) 14 (20.9%) 0.240 12 (16.7%) 11 (17.2%) 0.503
3.7. Developing a Preoperative Clinical and Imaging-Based Nomogram for Patients Resectable
Pancreatic Cancer
Based on the results of multivariate analysis of 82 patients with resectable pancreatic cancer,
a nomogram to predict one- and five- year DFS and OS was derived (Figure S1). The nomogram
included the same parameters as those of entire study population. The model performance, quantified
by Harrell’s c-statistics, was 0.716 (SE = 0.040) for DFS and 0.668 (SE = 0.039) for OS (Table S4).
Calibration plots showed good agreement between actual and predicted probability for both DFS
and OS (Figure S2). Internal validation performed using 200 bootstrap resampling revealed that
Harrell’s C-index and iAUC of the suggested nomogram was 0.695 (95% CI, 0.622-0.763) and 0.693
(95% CI, 0.619–0.755) for DFS, and 0.722 (95% CI, 0.646–0.796) and 0.713 (95% CI, 0.641–0.794) for
OS, respectively. Based on the 50% probability of five-year survival calculated from the nomogram,
patients were divided into low- and high-risk groups. There were statistically significant differences
between risk groups regarding both DFS and OS (both P < 0.001; Figure S3).
4. Discussion
In the present study, a nomogram based on preoperative clinical and radiologic parameters was
derived to predict postoperative oncologic outcomes of patients with pancreatic head cancer who
underwent curative-intent surgery without neoadjuvant therapy. It included symptoms at diagnosis,
preoperative serum CA 19-9 dichotomized at 34 U/mL, and four CT features (necrosis, possible venous
invasion, suspected metastatic regional LN, and associated pancreatitis or pseudocyst) to predict one-
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and five-year DFS and OS. Kaplan-Meier analysis revealed that the two risk groups defined by the
proposed nomogram had clearly different survival rates, a potential advantage of the nomogram
(P < 0.001).
Brennan et al. proposed a nomogram to predict postoperative disease-specific survival of patients
undergoing resection of pancreatic cancer [18], which was externally validated for large populations
in the U.S. [23] and Europe [24,25]. Its concordance index was 0.64 and 0.61–0.62 in the external
validation [23,24]. Brennan’s nomogram seems to show better performance than our nomogram (iAUC
for OS, 0.579 (95% CI, 0.536–0.626)). However, they included all patients with resected pancreatic
cancer regardless of tumor location, although a majority (89.4% (496 of 555)) of the cancers were found
in the head. Moreover, along with clinical information (age, sex, presence of back pain or weight
loss), postoperative information, such as surgical extent and pathologic status, were the main factors
in their nomogram. Recently, a Chinese group proposed a nomogram that considered both clinical
and preoperative CT findings to predict OS in patients with resectable pancreatic head cancer [26].
However, they only included patients with borderline resectable cancer with suspected venous invasion
on CT. No study considering various preoperative CT findings along with clinical information to
predict prognosis has been reported so far for patients with radiologically resectable and borderline
resectable pancreatic head cancer. Furthermore, we found the same trend when analyzing patients
with borderline resectable or resectable pancreatic cancer and when analyzing only patients with
resectiable pancreatic cancer.
Tumor necrosis caused by hypoxia is generally regarded as a poor prognostic factor and was
reported as an independent prognostic factor of DFS in a past pathologic study [27]. In our study,
necrosis on CT was observed in 19.9% (27 of 136) patients, and median serum CA 19-9 was marginally
higher (1297.76 (SE, 457.12) vs. 428.10 (SE, 138.94); P = 0.078) in patients with necrosis on CT than
those without.
Although pathologic node-positivity is an important predictor of five-year OS [28], there is an
obvious limitation in preoperative diagnosis of LN metastasis with imaging [29]. In our study, when a
short diameter of 8 mm was used as a cutoff for regional LN metastasis on CT, the diagnostic sensitivity
and specificity was 40.2% (35 of 87) and 81.6% (40 of 49), respectively. The sensitivity was higher than
previous studies using 10 mm as a cutoff (14%) with comparable specificity. LN metastasis seems to
be a poor prognostic factor for tumor recurrence and OS, although statistically significant only for
recurrence. Vyas et al. reported the presence of LN 10 mm or larger on CT regardless of pathologic
LN status as a prognostic factor [30]. As the systemic inflammatory response syndrome with high
preoperative c-reactive protein levels has been reported as a poor prognostic factor for pancreatic
cancer [31], they suggested that an enlarged LN might be associated with systemic inflammation.
Shen et al. also reported node-positivity on CT as a prognostic factor in patients with borderline
resectable pancreatic head cancer, although they did not clarify the definition of positive LN on CT [26].
In our study, the LN positivity assessed by CT was not a significant factor in predicting survival when
analyzed in patients only with resectable pancreatic cancer, as opposed to patients with borderline or
resectable pancreatic cancer. No evidence was found in our study for changes in the upfront surgical
policy for patients with resectable pancreatic cancer with suspected local LN metastases in CT but
without other risk factors.
In our study, the presence of pancreatitis or pseudocyst on CT was a good prognostic factor for
both DFS and OS. One-year OS has been reported to be higher in patients with pancreatic cancer
associated with acute pancreatitis than all patients [32]. Early-onset symptoms enabling early diagnosis
may be a reason for the higher OS. However, the presence of symptoms is a poor prognostic factor. Of
all patients, 77.9% (106 of 136) were symptomatic (jaundice (n = 65), abdominal pain (n = 48), weight
loss/anorexia (n = 22), nausea and/or vomiting (n = 4)) with higher serum CA 19-9 (716.33 (SE, 184.97)
vs. 192.4 (SE, 59.26); P = 0.008) and larger tumor size on surgical pathology (27.1 mm (SE, 0.82) vs.
23.5 (SE, 1.47); P =0.044) than asymptomatic patients. Considering that our population was entirely
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composed of patients with pancreatic head cancer, we can presume that the larger the tumor burden is,
the more likely it is to be symptomatic.
There are limitations in this study. First, all patients were allocated to the derivative set because
of the small population size, meaning that the validation method was limited to bootstrapping.
The generalizability of the nomogram should be externally validated with an independent population
before being applied to clinical practice. There is a possibility that critical variables infrequently
detected might have been neglected because of the small population size. In our study, venous invasion
on CT was a prognostic factor showing marginal statistical significance, whereas arterial involvement
and overall resectability on CT were not independent prognostic factors. Arterial involvement is
considered a more important prognostic factor than venous invasion in patients with borderline
resectable pancreatic cancer [33]. However, there were only four borderline resectable tumors with
arterial invasion, of which two were suspected for venous invasion. The low frequency of positive
findings might explain why this factor was not included in the model. In addition, it might be difficult
to differentiate pseudocysts from other cystic lesions such as retention cysts. To reduce misdiagnosis,
cystic lesions were evaluated by an experienced radiologist and they were regarded positive only when
there was no need to differentiate them from other diagnosis.
In conclusion, the present nomogram based on preoperatively detectable clinical and radiologic
parameters can potentially help clinicians decide management plans for pancreatic head cancers which
are radiologically resectable and candidates for curative-intent surgery without neoadjuvant therapy.
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